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ABSTRACT
Glucose is the preferred source of energy in activated inflammatory
cells. Glucose uptake into the cell is ensured by a family of glucose
uptake transporters (GLUTs), which have been identified as off-target
molecules of the HIV protease inhibitor ritonavir. In this study, we
examined the effect of ritonavir on inflammation in vitro and in vivo.
Peripheral blood mononuclear cells (PBMCs) were activated with
anti-CD3 in the presence or absence of ritonavir and analyzed by flow
cytometric analysis. Frequencies of CD4+ cells were significantly
affected by ritonavir (CD69+ P=3E-05; CD134 P=4E-06; CD25+
P=E-07; central memory P=0.02; effector P=6E-03; effector
memory P=6E-05). To corroborate that inflammation has a
metabolic effect in vivo, a mouse model was used that is based on
immunocompromised NOD-scid IL-2Rγnull mice reconstituted with
PBMCs from patients with ulcerative colitis (UC). Inflammation had a
significant effect on amino acid (AA) levels (Glu P=1E-07, Asp P=1E-
04). Principal component analysis (PCA) discriminated between
unchallenged and challenged groups. Finally, the efficacy of ritonavir
was tested in the same mouse model. Dependent variables were
clinical and histological scores, frequencies of human leukocytes
isolated from spleen and colon, and levels of AA in sera of mice. Mice
benefited from treatment with ritonavir as indicated by significantly
decreased colon (P=7E-04) and histological (P=1E-04) scores,
frequencies of M2 monocytes (CD14+ CD163; P=0.02), and Glu
levels (P=2E-05). PCA discriminated between control and challenged
groups (P=0.026). Thus, inhibition of glucose uptake might be a
promising therapeutic intervention point for active UC.
KEY WORDS: Ulcerative colitis, Metabolic switch, Glucose
transporter, Ritonavir, NOD-scid IL-2Rγnull, Mouse model,
Inflammation
INTRODUCTION
The energy supply of inflammatory cells relies on three sources:
glycolysis, oxidation of lipids, and amino acid (AA) metabolism. In
homeostasis, when the major task of inflammatory cells is the
maintenance of tolerance, lipids are the preferred source as lipid
oxidation is the most efficient albeit slowest pathway to generate ATP
(for a review, see O’Neill et al., 2016). The response to an assault,
however, requires the immediate activation, proliferation and
differentiation of inflammatory cells, their migration to sites of
inflammation, and expression of cytokines, growth factors and
chemokines. These processes demand prompt energy supply,
which is met by a metabolic switch from lipid oxidation to
glycolysis to ensure swift ATP generation and the synthesis of
biosynthetic intermediates, albeit at the expense of efficiency.
Therefore, the dependence on glycolysis might offer an Achilles’
heel of inflammatory cells.
This aspect is of great interest for treatment of chronic
inflammatory diseases. Although great therapeutic improvement
has been made with the approval of highly effective biologicals like
anti-TNFα antibodies (infliximab, adalimumab and certolizumab),
the anti-integrin-α4β7 antibody vedolizumab and the anti-IL12/23
antibody ustekinumab, many patients respond insufficiently to
these drugs or develop a secondary loss of response and require
additional or different treatments. Metabolic profiling of patients
with ulcerative colitis (UC) and Crohn’s disease (CD) in
comparison to non-diseased individuals corroborated the
assumption that, in these diseases, glycolysis is the preferred
metabolic pathway (Dawiskiba et al., 2014; Bjerrum et al., 2017).
Hence, targeting glycolysis might open up entirely novel treatment
options for UC or CD. In addition to metabolites related to
glycolysis, these studies have shown that, in sera of UC and CD
patients, levels of AAs were either up [glutamic acid (Glu)] or down
[histidine (His)] (Hisamatsu et al., 2015).
Targeting glucose uptake has already been followed for the
treatment of tumors whose energy demands and resources are similar
to those of inflammatory cells. The dependence on glycolysis of
tumor cells was observed by Otto Warburg approximately 100 years
ago and is known as theWarburg effect (Warburg, 1956). As glucose
uptake is the key rate-limiting step of glycolysis, inhibiting glucose
transporters (GLUTs) offers a promising therapeutic approach.
GLUTs encompass a wide family of integral membrane proteins
that are differentially expressed in various tissues. The development
of GLUT inhibitors for the treatment of cancer has further gained
momentum by the observation that ritonavir, which has originally
been developed as an inhibitor of HIV protease, coincidentally
inhibits the members 1 and 4 (Murata et al., 2000; Hertel et al., 2004;
Vyas et al., 2010) of the GLUT family.
Preclinical studies in vitro and in vivo have shown that ritonavir
alone and in combination with metformin inhibits proliferation of
multiple myeloma and chronic lymphocytic leukemia cells, both of
which exhibit abnormal glucose metabolism (Adekola et al., 2015;
Dalva-Aydemir et al., 2015). The positive outcome of these
experiments resulted in a first clinical trial to test metformin
hydrochloride and ritonavir in patients with relapsing or refractoryReceived 22 June 2018; Accepted 2 October 2018
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multiple myeloma or chronic lymphocytic leukemia (http://
clinicaltrials.gov/ct2/show/NCT02948283).
Recently, we have developed a mouse model of UC, which is
based on NOD-scid IL-2Rγnull (NSG) mice reconstituted with
peripheral blood mononuclear cells (PBMCs) from patients with
UC (NSG-UC mice) (Palamides et al., 2016; Jodeleit et al., 2017;
Al-amodi et al., 2017). In this model, the development of symptoms
is induced by rectal challenge with ethanol and requires immune
reconstitution with PBMCs from patients with active disease.
In light of the metabolic switch observed in UC patients, we
evaluated ritonavir as a potential therapeutic for treatment of UC.
First, the effect of ritonavir on CD4+ T cells was tested in vitro.
Results indicate that ritonavir inhibited the activation of CD4+ T
cells. Secondly, glutamic and aspartic acid were identified as
potential biomarkers of inflammation in the NSG-UCmouse model.
Finally, ritonavir was tested in the NSG-UC mouse model. Results
indicate that ritonavir might be an attractive therapeutic for UC and
that AAs are powerful biomarkers in this model.
RESULTS
Ritonavir affects subsets of CD4+ T cells
Previous studies have shown that ritonavir inhibits proliferation and
survival in multiple-myeloma and chronic-lymphocytic-leukemia
cell lines in vitro and in vivo by shutting down the glycolytic
pathway (Adekola et al., 2015; Dalva-Aydemir et al., 2015).
However, these cell lines per se exhibit an abnormal glucose
metabolism – a condition that we would not expect in unchallenged
inflammatory cells. We therefore examined the response to ritonavir
in subtypes of CD4+ T cells challenged with anti-CD3. PBMCs
were isolated from five donors and experiments performed in
triplicates. A total of 1×106 cells were incubated with or without
anti-CD3 antibodies for 72 h in the presence and absence of
ritonavir and subjected to flow cytometric analysis as described in
the Materials and Methods. (For a definition of cells and gating
strategy, see Table S2 and Fig. S1). As shown in Fig. 1A and
Table S3, frequencies of CD4+ cells increased in response to anti-
CD3; however, this effect was not significant. Upon the addition of
ritonavir, frequencies of CD4+ cells returned to levels of the control
group, and the difference between the ritonavir-treated group and
the anti-CD3-treated group was significant, whereas that between
the ritonavir-treated group and the control group was not. Exposure
to anti-CD3 antibodies resulted in significantly increased
frequencies of CD25-, CD134- and CD69-expressing CD4+ cells,
indicating a general activation of CD4+ T cells. Ritonavir reversed
these effects with the exception of CD4+ CD69+ cells, whose
frequencies even further increased. Challenge with anti-CD3
antibodies had no effect on naïve or effector CD4+ T cells, and
only a minor effect on effector memory CD4+ T cells, whereas the
frequencies of central memory CD4+ T cells increased significantly.
Ritonavir had opposing effects on effector, central memory and
effector memory CD4+ T cells. Ritonavir decreased frequencies of
effector and central memory CD4+ T cells, whereas frequencies of
effector memory cells increased. To ensure that ritonavir did not
affect the viability of PBMCs, PBMCs from two different donors
were analyzed for LIVE CD4+ and LIVE CD14+ cells using
Zombie Green™ Fixable Viability Kit. As shown in Fig. 1B, the
viability of CD4+ T cells was not impaired by ritonavir.
Glutamic and aspartic acid are metabolic markers for
inflammation in the NSG-UC mouse model
As previous studies have identified AAs as potential markers of
inflammation in UC and Crohn’s disease (Dawiskiba et al., 2014;
Bjerrum et al., 2017), we measured AAs in serum of NSG-UC mice
in response to challenge with ethanol. The study was performed as
described previously (Palamides et al., 2016; Jodeleit et al., 2017).
NSG mice were reconstituted with PBMCs and challenged
according to a standard protocol as described in the Materials and
Methods. At 8 days post-reconstitution, the mice were divided into
two groups: one was left unchallenged (control), the other was
challenged by rectal application of ethanol. Each group contained
four to six animals and the experiment was repeated with four
donors. Donors exhibited a simple clinical colitis activity index
(SCCAI) (Walmsley et al., 1998) from one to seven. One donor
was therapeutically naive, one was treated with mesalazine
and vedolizumab, one with mesalazine, vedolizumab and
glucocorticoids and one with glucticorticoids. Upon challenge
with ethanol, mice stools became soft or liquid, the animals lost
weight and the clinical activity score was elevated. Control animals
displayed hardly any symptoms. Symptoms were classified
according to a clinical score described in the Materials and
Methods. Upon challenge, the clinical score increased
significantly (Fig. 2A; for complete data set see Table S4). This
observation was also corroborated by the colon score, which also
increased significantly. As shown in previous studies (Palamides
et al., 2016; Jodeleit et al., 2017; Al-amodi et al., 2017), histological
analysis of the colon revealed the influx of a mixed infiltrate of
leukocytes, edema, crypt loss and changes in the colon architecture
(not shown). The histopathological manifestations were classified
according to a histological score (Fig. 2A) and confirmed a
significant response to ethanol. Prior to autopsy, serum samples
were collected and subjected to AA analysis. Inflammation resulted
in significantly elevated levels of glutamic and aspartic acid
(Fig. 2A). Receiver operating characteristic (ROC) analysis
identified both AAs as biomarkers with high potential to
discriminate between challenged and unchallenged mice
(glutamic acid: AUC=0.91; aspartic acid: AUC=0.87) (Fig. 2B).
For further analysis, leukocytes were isolated from spleen and
subjected to flow cytometric analysis as described in the Materials
and Methods. Correlation analysis revealed a high correlation
coefficient between both AAs and the clinical score, colon score and
histological score, and with activated CD4+ CD69+ and CD4+
CD103+ T cells (Table 1), and thus corroborated the in vitro
experiments. As observed in the human studies, levels of histidine
declined upon challenge (Hisamatsu et al., 2015).
To further evaluate the combined power of the parameters to
discriminate between the two groups, a principal component analysis
(PCA) was performed to include the clinical, colon and histological
scores, and levels of glutamic and aspartic acid. Scatter plots of PCA
scores of single mice, with ellipses indicating confidence regions,
depict mice of the control group as a closely clustered group, whereas
ethanol-challenged mice are more distributed (Fig. 3). Multivariate
regression analysis of the five parameters revealed an R2 predicted
value of 0.62 and discriminating analysis based on partial least square
that 95% of all predictions were correct.
Treatment with ritonavir ameliorates disease phenotype in
NSG-UC mouse model
To examine the effect of ritonavir in vivo, NSG-UC mice were
treated with ritonavir. The study was performed as in the previous
experiment; this time, however, the challenged group was treated
with vehicle (ethanol+vehicle) and a third group was added
consisting of mice challenged with ethanol and treated with
ritonavir (ethanol+ritonavir). The study was repeated with
PBMCs from four different UC patients (Table 2). (For the
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complete data set, please see Table S5.) The clinical score increased
upon challenge and almost normalized with treatment of ritonavir
(Fig. 4C). This observation was corroborated by macroscopic
inspection of the colons. As shown in Fig. 4Ac, colons of
ritonavir-treated mice appeared normal as compared to colons of
ethanol-challenged mice (Fig. 4Ab), which exhibited the typical
dilation and soft stools. Histological analysis further confirmed
these results. Challenge with ethanol resulted in severe colon
pathology to include crypt alterations, edema and fibrosis
(Fig. 4Bb), whereas histological sections of ritonavir-treated mice
appeared almost normal (Fig. 4Bc) (for scoring data, see Table S6).
This observation was corroborated by the histological score, which
was significantly reduced in the ritonavir-treated group (Fig. 4C).
As subtypes of monocytes had been previously identified as
inflammatory markers in the NSG-UC mouse model (H.J., O.A.-A.
and G.B. et al., unpublished), human leukocytes were isolated from
the spleenofmice and subjected to flowcytometric analysis. Themost
profound effect of ritonavir was found on naïve CD4+ T cells and on
M2 monocytes (CD14+ CD163+), whose frequencies were
significantly elevated upon challenge with ethanol and reduced to
Fig. 1. Ritonavir affects frequencies of CD4+ T-cell subtypes. Flow cytometric analysis of PBMCs that were incubated for 3 days in the presence or absence of
anti-CD3 antibodies and ritonavir. Experiments were performed in triplicate. (A) Frequencies of CD4+ T cells and subtypes thereof depicted as boxplot diagrams
(donor n=5). For comparison of groups, ANOVA followed by Tukey’s HSD was conducted. Boxes represent upper and lower quartiles, whiskers represent
variability and outliers are plotted as individual points (***P≤0.001, **P≤0.01, *P≤0.05, n.s., non-significant). Labels given on x-axes on the bottom rowapply to all
charts. (B) Frequencies of LIVE CD4+ cells depicted as barplots. Mean values are given; error bars are s.d. Results from two different donors are given.
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normal levels in the presence of ritonavir (Fig. 4D). In contrast,
frequencies of CD1a-expressing CD14+ monocytes were not
significantly affected by treatment with ritonavir (Table S5). The
anti-inflammatory effect of ritonavir was corroborated by analysis of
AA levels. Glutamic and aspartic acids levels normalized upon
treatment with ritonavir (Fig. 4E). Histidine levels increased upon
treatment; however, this effect was not significant.
To examine the effect of ritonavir on inflammation in the
compartment of the colon, leukocytes were isolated and subjected
to flow cytometric analysis (Fig. 5). Frequencies of human CD11b
+ macrophages, CD14+ monocytes, CD19+ B cells, and
neutrophils were reduced upon treatment with ritonavir, whereas
CD4+ T cells were unaffected (for gating strategy see Fig. S2).
The strongest effect was observed on CD103- and CD134-
expressing CD4+ T cells, mature CD11b+ macrophages and
CD14+ monocytes, and M1 (CD14+ CD64+) and M2 (CD14+
CD163) monocytes; however, differences did not reach
significance.
As observed previously, PCA clearly segregated the challenged
group from the control, and the treated group clustered with the
control group when clinical score, histological score, and aspartic
and glutamic acid levels were used as parameters (Fig. 6). Ordinal
regression analysis revealed the significance of this model [Pr
(Chi)=0.004], and these parameters resulted in a significant
discrimination of the control group and the ethanol-challenged
group (P=0.02), and the ethanol-challenged group and the ritonavir-
treated group (P=0.05).
Fig. 2. Glutamic and aspartic acid are inflammatory
markers in the NSG-UC mouse model. NSG-UC mice were
engrafted with PBMCs derived from UC patients, challenged
with 10% ethanol at day 8, and 50% ethanol at days 15 and 18.
(A) Amino acid (AA) levels and clinical and histological scores
depicted as boxplot diagrams [donors n=3; unchallenged
control group (control n=10); ethanol-challenged group
(Challenge n=11)]. For comparison of groups, ANOVA followed
by Tukey’s HSD was conducted. Boxes represent upper and
lower quartiles, whiskers represent variability and outliers are
plotted as individual points (***P≤0.001, *P≤0.05). Labels
given on x-axes on the bottom row apply to all charts. (B) ROC
curve for glutamic and aspartic acid in discriminating control
and challenged groups.
Table 1. Correlation analysis of aspartic and glutamic acid serum levels
with clinical, colon and histological scores and activated CD4+ T cells.
Correlation coefficients
Cells Aspartic acid (P;CI) Glutamic acid (P;CI)
Clinical score 0.3 (0.007; 0.1-1) 0.44 (0.001; 0.18-1)
Histological score 0.42 (0.0007; 0.21-1) 0.58 (2E-6; 0.4-1)
Colon score 0.39 (0.0005; 0.2-1) 0.46 (5E-5; 0.28-1)
CD4+ CD69+ 0.36 (0.008; 0.12-1)
CD4+ CD103+ 0.61 (7E-6; 0.42-1) 0.41 (0.03; 0.17-1)
Method=Pearson; numbers display correlation coefficients, followed by
P-values and confidence intervals (CIs) in parentheses. Sample size: n=71.
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DISCUSSION
The metabolic requirements of cancer cells differ from immune cells
with regard to their capacity to modulate and adapt energy supply.
Whereas cancer cells are continuously dependent on glycolysis due to
their proliferative and migratory nature, immune cells acquire these
traits upon challenge and modulate metabolic pathways accordingly.
Therefore, the observation that activation of CD4+ T cells and the
increase of frequencies of central memory CD4+ T cells in response
to anti-CD3were reversed by ritonavir did not come as a surprise. We
did not expect, however, for ritonavir to increase the frequencies of
effector memory cells. Central memory and effector memory cells
differ with regard to expression of CD62L and CCR7, and, hence,
ritonavir would impair the ability of memory cells to migrate to
lymph nodes to be exposed to dendritic cells. We also did not expect
that ritonavir increases the frequencies of early activated CD4+CD69
+ T cells. Further studies have to show which subtypes of cells are
activated to understand the specific responses to ritonavir.
In the NSG-UC mouse model, the induction of inflammation had
a significant effect on glutamic and aspartic acid, tryptophan and
histidine levels, and corroborated results obtained in UC patients
(Dawiskiba et al., 2014; Hisamatsu et al., 2015; Bjerrum et al.,
2017). ROC analysis indicated that glutamic and aspartic acid were
biological markers to discriminate with high sensitivity and
specificity between unchallenged control and ethanol-challenged
mice. PCA of the colon and histological scores, and glutamic and
aspartic acid levels revealed a clustering of these two groups. This
result is a major advantage as it most probably allows for evaluating
more subtle differences in efficacy.
Mice benefitted significantly from treatment with ritonavir as
indicated by the four parameters: clinical and histological scores and
glutamic and aspartic acid levels in serum. PCA distinguished
between control and challenged groups, and treatment with ritonavir
resulted in clustering closer to the control group. Analysis of the
human leukocytes isolated from spleen revealed that the most
pronounced effect of ritonavir was observed in monocytes. Unlike
in the in vitro experiments, ritonavir had no effect on activation of
CD4+ T cells (data not shown).
An effect of ritonavir was, however, observed when human
leukocytes isolated from colon were analyzed. As observed in the
in vitro experiments, frequencies of activated CD4+ T cells declined
with the exception of CD4+ CD69+ T cells. Likewise, frequencies
of mature CD11b+ macrophages and CD14+ monocytes decreased,
as well as M2 monocytes.
In summary, this study shows that inflammation in the NSG-UC
mice has a significant metabolic effect in the NSG-UC model,
which partially reflects the metabolic effects observed in UC
patients. AA levels are potential biological markers of inflammation
so might improve the evaluation of efficacy of therapeutics. The
positive outcome of the preclinical study in the NSG-UC model
suggests that UC patients might benefit from adjuvant treatment
with ritonavir during times of active disease, and might encourage
the development of novel GLUT inhibitors.
MATERIALS AND METHODS
Ethical considerations
All donors gave informed written consent and the study was approved by the
Institutional Review Board (IRB) of the Medical Faculty at the University of
Munich (2015-22).
Animal studies were approved by the ethics committee of the government
of Upper Bavaria, Germany (55.2-1-54-2532-76-15) and performed in
compliance with German Animal Welfare Laws.
Isolation of PBMCs and engraftment
Isolation of PBMCs and engraftment was performed as described
previously (Jodeleit et al., 2017). Sixty milliliters of peripheral blood
were collected in trisodium citrate solution (S-Monovette, Sarstedt,
Nürnberg, Germany) from the arm vein of patients suffering from UC
or healthy control subjects. The blood was diluted with Hank’s balanced
salt solution (HBSS, Sigma-Aldrich, Deisenhofen, Germany) in a 1:2
ratio and 30 ml of the suspension were loaded onto LeucoSep tubes
(Greiner Bio One, Frickenhausen, Germany). PBMCs were separated by
centrifugation at 400 g for 30 min and no acceleration. The interphase was
extracted and diluted with phosphate buffered saline (PBS) to a final
volume of 40 ml. Cells were counted and centrifuged at 1400 g for 5 min.
The cell pellet was resuspended in PBS at a concentration of 4×106 cells
in 100 µl.
Six- to eight-week-old NSG mice were engrafted with 100 µl cell
suspension into the tail vein on day 1.
Cell culture
PBMCs of healthy individuals and UC patients were isolated. The cell pellet
was resuspended in RPMI (Thermo Fisher Scientific, Waltham, MA, USA)
at a concentration of 1×106 cells/ml. Additionally, 500 µl RPMI with 10%
FCS and 1% penicillin-streptomycin (Sigma-Aldrich, St Louis, MO, USA)
were added to each well and sample. Wells containing PBMCs and RPMI or
PBMCs, RPMI and anti-CD3 (1 µg/ml, BioLegend, San Diego, CA, USA)
served as negative and positive controls, respectively. Ritonavir was
dissolved in 100% ethanol (10 mg/ml). For analysis of the effect of
ritonavir, 100 µg/ml ritonavir (Sigma-Aldrich, Deisenhofen, Germany) was
added. Cells were incubated for 72 h. The content of each well was
centrifuged at 1400 g for 5 min. The pellet was resuspended in FACS buffer
and labeled for flow cytometry.
Fig. 3. PCAdiscriminates between control and ethanol-challenged group.
PCA score and loading plots (donors n=4, each group n=17). Sample size:
donor n=4, (‘A’, green) control n=17, (‘B’, orange) challenge n=17. Ellipses
display confidence areas of 0.95.
Table 2. Basic patient demographics
Donor Age (years) Gender Medication SCCAI
UC1 26 M Adalimumab 9
UC2 80 F Mesalazine 5
UC3 54 M None 3
UC4 30 M Vedolizumab 11
M, male; F, female; SCCAI, simple clinical colitis activity index.
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Fig. 4. NSG-UC mice benefit from treatment with ritonavir. NSG-UC mice were engrafted with PBMCs derived from UC patients (n=4), challenged with 10%
ethanol at day 8, and 50% ethanol at days 15 and 18, and treated with 20 mg/kg body weight ritonavir or carrier at days 7, 8 and 14-20. (a) Unchallenged
control (Control n=15); (b) challenged control (Ethanol+Vehicle, n=21); (c) challenged and treated with ritonavir (Ethanol+Ritonavir, n=27). (A) Macrophotographs
of colons at autopsy. (B) Photomicrographs of H&E-stained sections of distal parts of the colon from mice reconstituted with the same donor. Thin arrow
indicates edema and influx of inflammatory cells; bold arrows indicate fibrosis. (C) Clinical, colon and histological scores of NSG-UC mice. (D) Frequencies of
CD14+ subtypes isolated from spleens of mice. (E) Aspartic and glutamic acid serum levels depicted as boxplot diagrams (donor n=2, Control n=10, Ethanol
+Vehicle n=10, Ethanol+Ritonavir n=11). For comparison of groups, ANOVA followed by Tukey’s HSD was conducted. Boxes represent upper and lower
quartiles, whiskers represent variability and outliers are plotted as individual points (***P≤0.001, **P≤0.01, *P≤0.05, n.s., non-significant). Labels given on x-axes
on the bottom row apply to all charts.
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To differentiate between live and dead cells, staining with Zombie
Green™ Fixable Viability Kit (BioLegend) was performed according to the
manufacturer’s instructions.
Animal study protocol
NOD-scid IL-2Rγnull (NSG) mice were obtained from Charles River
Laboratories (Sulzfeld, Germany). Mice were kept under specific pathogen-
free conditions in individually ventilated cages in a facility controlled
according to the Federation of Laboratory Animal Science Association
(FELASA) guidelines. Following engraftment (day 1), mice were pre-
sensitized by rectal application of 150 µl of 10% ethanol on day 8 using a
1 mm cat catheter (Henry Schein, Hamburg, Germany), which is normally
used for urinary catheterization in cats. In our case, we used it for rectal
application of ethanol because of a similar diameter of a mouse rectum and a
cat’s urethra. The catheter was lubricated with Xylocain©Gel 2%
(AstraZeneca, Wedel, Germany). Rectal application was performed under
general anesthesia using 4% isofluran. Following application, mice were
kept at an angle of 30° to avoid ethanol dripping. On days 15 and 18, mice
were challenged by rectal application of 50% ethanol following the protocol
of day 8. Mice were sacrificed by cervical dislocation on day 21.
Ritonavir was dissolved in 100% ethanol (100 mg/ml) and diluted with
PBS to a final concentration of 5 mg/ml of 5% ethanol. Mice were treated by
intraperitoneal application of 500 µg or 5% ethanol in PBS (vehicle) on days
7, 8 and 14-20. The dosage corresponds to 20 mg/kg body weight, which is
recommended for maintenance therapy of HIV patients and calculated for a
25 g mouse.
Clinical activity score
The assessment of severity of colitis was performed daily according to the
following scoring system: loss of body weight: 0% (0), 0-5% (1), 5-10% (2),
10-15% (3), 15-20% (4). Stool consistency: formed pellet (0), loose stool or
unformed pellet (2), liquid stools (4). Behavior: normal (0), reduced activity
(1), apathy (4) and ruffled fur (1). Body posture: intermediately hunched
posture (1), permanently hunched posture (4). The scores were added daily
into a total score with a maximum of 18 points per day. Animals who
suffered from weight loss >20%, rectal bleeding, rectal prolapse, self-
isolation or a severity score >7 were euthanized immediately and not taken
into count.
Histological analysis
Samples fromdistal parts of the colonwere fixed in 4% formaldehyde for 24 h
before storage in 70% ethanol and were routinely embedded in paraffin.
Samples were cut into 3-µm sections and stained with hematoxylin and eosin
(H&E). Epithelial erosions were scored as follows: no lesions (0), focal
lesions (1), multifocal lesions (2), major damage with involvement of basal
membrane (3). Inflammation was scored as follows: infiltration of
few inflammatory cells into the lamina propria (1), major infiltration of
inflammatory cells into the lamina propria (2), confluent infiltration of
inflammatory cells into the lamina propria (3), infiltration of inflammatory
cells including tunica muscularis (4). Fibrosis was scored as follows: focal
fibrosis (1), multifocal fibrosis and crypt atrophy (2). The presence of edema –
minimal (1), moderate (2), severe (3), hyperemia (1) and crypt abscess (1) –
was scored with additional points in each case. The scores for each criterion
were added to give a total score ranging from 0 to 12. Images were taken with
a Zeiss AxioVert 40 CFL camera. Figures show representative longitudinal
sections in original magnification. In Adobe Photoshop CS6, a tonal
correction was applied in order to enhance contrasts within the pictures.
Isolation of human leukocytes
To isolate human leukocytes from murine spleen, spleens were minced and
cells filtrated through a 70 µl cell strainer (Greiner Bio-One, Frickenhausen,
Germany) followed by centrifugation at 1400 g for 5 min and resuspended
Fig. 5. Treatment with ritonavir affected frequencies of human leukocytes isolated from colon of NSG-UC mice. Leukocytes were isolated from mice
described in Fig. 4. Data were combined from four different experiments and samples from each group were pooled from six mice (Control n=4, Ethanol+Vehicle
n=4, Ethanol+Ritonavir n=4). Mean values are given; error bars are s.d. Quantification was performed using flow cytometric analysis.
Fig. 6. PCA discriminates between the control group, ethanol-challenged
group and ritonavir-treated group. PCA scores and loading plots (‘A’,
green=Control; ‘B’, orange=Ethanol+Vehicle; ‘C’, blue=Ethanol+Ritonavir).
For comparison of groups, ordinal regression analysis was performed
(*P≤0.05). Control group versus Ethanol+Vehicle P=0.02; Ethanol+PBS
P=0.05.
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in FACS buffer (1× PBS, 2 mM EDTA, 2% FCS) (Jodeleit et al., 2017). For
further purification, cell suspensions were filtrated using a 35-µm cell
strainer (Greiner Bio-One) and then labeled for flow cytometry analysis.
Isolation of LPMCs
For isolation of lamina propria mononuclear cells (LPMCs), a modified
protocol ofWeigmann et al. (2007) was used. Thewashed and minced colon
was pre-digested for 20 min in pre-digestion solution containing 1× HBSS
(Thermo Scientific, Darmstadt, Germany), 5 mM EDTA, 5% FCS, 100 U/
ml penicillin-streptomycin (Sigma-Aldrich) in an orbital shaker with slow
rotation (40 g) at 37°C. Epithelial cells were removed by filtering through a
nylon filter. Following washing with PBS, the remaining colon pieces were
digested twice for 20 min in digestion solution containing 1× RPMI
(Thermo Scientific), 10% FCS, 1 mg/ml collagenase A (Sigma-Aldrich),
10 KU/ml DNase I (Sigma-Aldrich) and 100 U/ml penicillin-streptomycin
(Sigma-Aldrich) in an orbital shaker with slow rotation (40 g) at 37°C
(Weigmann et al., 2007). Isolated LPMCs were collected by centrifugation
at 1400 g for 5 min and resuspended for FACS analysis. Cell suspensions
were filtrated one more time using a 35-μm cell strainer for further
purification before labeling the cells for flow cytometry analysis.
Flow cytometry analysis
Labeling of human leukocytes was performed according to Table S1. All
antibodies were purchased from BioLegend and used according to the
manufacturer’s instructions. Antibodies were diluted 1:200. Flow cytometry
was performed using a BD FACSCanto II™ and analyzed with FlowJo 10.1
software (FlowJo LLC, OR, USA). Cells were quantified according to the
gating strategy depicted in Fig. S1.
Detection of amino acids
Samples were prepared according to the manufacturer’s instructions.
Following incubation of 100 µl of serum with internal standards for
5 min, 25 µl of 15% 5-sulfosalicylic acid was added and samples were
centrifuged at 9000 g for 15 min at 4°C. Supernatants were filtered through a
0.2-µm membrane and 75 µl of lithium loading buffer was added. Samples
were analyzed by the AA analyzer Biochrom 30+ (Biochrom Ltd,
Cambridge, UK).
Statistics
All statistical analysis was performed with R: A language and environment
for statistical computing (R Foundation for Statistical Computing, Vienna,
Austria; https://www.R-project.org/) and BRB Array Tools (https://brb.nci.
nih.gov/BRB-ArrayTools/). Variables were represented with mean, standard
deviation and median values. A two-sided Student’s t-test and a confidence
level=0.95 was used to compare binary groups and, for more than two
groups, ANOVA followed by Tukey’s HSD was conducted. For correlation
analysis, Pearson correlation was used. To minimize the risk of overfitting,
multivariate regression models were performed applying the kernelpls fit
method and performing a leave one out cross validation procedure. For
PCA, a confidence interval of 0.95% was used.
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Figure S1. Gating strategy  (A) central memory, effector memory, naive and effector CD4+ cells; (B) Th1, Th2, Th17 and Th22 T-cells; 
(C) activated CD4+ T-cells and Tregs; (D) CD11b+ macrophages; (E) CD14+ monocytes. Leukocytes were labeled as described in 
Material and Methods using antibodies listed in Table S1. 
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Figure S2. Gating strategy for leukocytes isolated from colon. (A) B cells, human neutrophiles; (B) activated CD4+ T-cells; (C) 
CD14+ monocytes (D) CD11b+ macrophages. Leukocytes were labeled as described in Material and Methods using antibodies listed in 
Table S1. 
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Table S1. Antibodies used to label leucocytes 
Surfacemarker (anti 
human) 
Colour Clone Catalogue Number 
CD19 Peridine-chlorophyll-
protein complex 
cyanine dye (PerCP-
CyTM 5.5) 
HIB19 302230 
CD38 Phycoerythrin (PE) HB-7 356603 
CD27 Pe-Cy7 M-T271 356411 
IgD Fluorescin 
isothiocyanate (FITC) 
IA6-2 348217 
CD4 Allophycocyanin 
(APC)- Cy7 
OKT4 317417 
CD62L FITC DREG-56 304803 
CD45RO PE UCHL1 304205 
CD45RA Pe-Cy7 HI100 304125 
CCR7 APC G043H7 353213 
CD8 PerCP-CyTM 5.5 HIT8a 300923 
CD103 APC Ber-ACT8 350215 
CD25 PE-Cy7 BC96 302611 
CD14 APC-Cy7 HCD14 325619 
CCR2 PE-Cy7 K036C2 357211 
CD80/86 PerCP-CyTM 5.5 IT2.2 305419 
TSLPR* APC 1B4 322807 
CD1a (biotin)/secondary 
Ab streptavidin 
FITC HI149 300112 
CD64 PerCP-CyTM 5.5 10.1 305023 
CD163 FITC GHI/61 333617 
CD206 APC 15-2 321109 
CD16 PE 3G8 302007 
CD11b APC-Cy7 ICRF44 301341 
CD11c PE-Cy7 3.9 301607 
ECad PerCP-CyTM 5.5 67A4 324105 
CD127 PerCP-CyTM 5.5 A019D5 351321 
CD69 FITC FN50 310903 
CD134 (Ox40) PE Ber-ACT35 350003 
CXCR3 FITC G025H7 353703 
CCR4 PE L291H4 359411 
CCR6 PE-Cy7 G034E3 353417 
CCR10 APC 6588-5 341505 
* Thymic stromal lymphopoietin receptor
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Table S2. Cellular markers used to define immune cells 
Marker Definition 
CD19+ CD27+ IgD+ Unswitched memory B-cell 
CD19+ CD27+ IgD- Switched memory B-cell 
CD19+ CD38+ Plasma cell 
CD4+ CD45RO+ CD62L- CCR7- Effector memory CD4+ T- cell  
CD4+ CD45RO+ CD62L+, CCR7+ Central memory 
CD4+ CD103+ Mucosal regulatory  CD4+ T cell 
CD4+ CCR4+ Th2, effector regulatory T- cell 
CD4+ CD25+ CD127- Regulatory T-cell 
CD4+ CD134+ Activated CD4+ T cell 
CD4+ CD69+ Activated CD4+ T cell 
CD4+ CD25+ Activated CD4+ T cell 
CD14+ Monocytes (MC) 
CD14+ TSLPR*+ MC, expressing TSLPR 
CD14+ CD64+ M1MC 
CD14+ CD163+ CD206+ M2 MC, scavenging cells 
CD14+ CD1a MC CD1a expressing 
CD11b+ Conventional dendritic cells (cDC1) 
CD11b+ CD80/86+ cDC1, mature 
CD11b+ HLADR+ cDC1, presenting 
CD11b+ TSLPR*+ cDC1 TSLPR expressing 
CD11b+ CD1a+ cDC1 CD1a expressing 
* Thymic stromal lymphopoietin receptor
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Click here to Download Table S3 
Table S4. Complete data set from animal study 
Click here to Download Table S4 
Table S5. Complete data set from animal study testing ritonvir 
Click here to Download Table S5 
Table S6. 
Click here to Download Table S6 
Table S3. Complete data set from in vitro studies 
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